SiteOne’s first-quarter performance showed resilience in a challenging market, with the company delivering above-consensus ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

SiteOne Landscape Supply's SITE short percent of float has risen 3.72% since its last report. The company recently reported that it has 2.51 million shares sold short, which is 6.

Stargazer Industries Hawaiʻi — a Native Hawaiian-mixed, woman-owned company located in Kaʻū on the Big Island — is now at the ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as ...

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.

SiteOne’s STC-004 intends to address a highly pressing need to treat chronic pain without the potential of addiction and side effects associated with conventionally used opioids. “The global burden of ...

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

Investing.com -- Eli Lilly and Company (NYSE: LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non ...